US EditionBreakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session
- Leads Biolabs shared important findings from their ongoing phase Ib/II study conducted across multiple centers, assessing LBL-024 as a first-line therapy for patients with advanced extrapulmonary neuroendocrine carcinoma, during an oral presentation at the 2025 ASCO Annual Meeting.
- This trial followed regulatory clearance in April 2024 and Breakthrough Therapy and Orphan Drug Designations received in late 2024 to address EP-NEC’s unmet medical needs.
- Professor Shen Lin led a multi-center study involving 52 patients eligible for efficacy analysis, investigating the use of LBL-024 in combination with a chemotherapy regimen of etoposide and platinum agents.
- Results showed a 75.0% overall response rate and 92.3% disease control rate, with 57.7% of patients achieving over 50% tumor shrinkage, outperforming historical chemotherapy data.
- The data strongly support progressing LBL-024 to a critical late-stage clinical trial, demonstrating a manageable safety profile and promising potential for use in various cancer types beyond EP-NEC.
78 Articles
78 Articles
Bennington Banner
Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session
NANJING, China, May 31, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB bispecific antibody, in combination with etoposide plus…
Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session - PressReach
NANJING, China, May 31, 2025 /PRNewswire/ — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”) today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB bispecific antibody, in combination with etoposide plus platinum-based chemotherapy for treatment-naive patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The results were featured i…
Coverage Details
Bias Distribution
- 58% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
